drugset / Trial / NCT04991506
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Phase 1
Completed
30 enrolled
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.
Timeline
- Start
- 2021-10-15
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES102 | Unknown | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |